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Abstract
Background: Poor lifestyle choices are key in development and progression of preventable chronic diseases. The
purpose of the study was to design and test a program to mitigate the physical and fiscal consequences of
chronic diseases.
Methods: Here we report the outcomes for 429 participants with one or more chronic conditions, including
obesity, hypertension, hyperlipidemia and diabetes mellitus, many of whom had failed traditional disease
management programs, who enrolled into a comprehensive lifestyle intervention. The Lifestyle 180 program
integrates nutrition, physical activity and stress management interventions and was conducted at the Wellness
Institute of the Cleveland Clinic, United States. An intensive 6 week immersion course, with 8 hours of group
instruction per week, was followed by 3 follow-up, 4 hour-long sessions over the course of 6 months.
Results: Changes in biometric (weight, height, waist circumference, resting heart rate and blood pressure) and laboratory
variables (fasting lipid panel, blood glucose, insulin, hemoglobin A1c, ultra sensitive C-reactive protein) at 6 months were
compared with baseline (pre-post analysis). At week 30, biometric and laboratory data were available for 244 (57%) and
299 (70%) participants, respectively. These had a mean ± SD reduction in weight (6.8 ± 6.9 kg, P < 0.001), waist
circumference (6.1 ± 7.3 cm, P < 0.001), glucose (4.5 ± 29.6 mg/dL or 0.25 ± 1.64 mmol/L, P = 0.009), triglycerides (26.4 ±
58.5 mg/dL or 0.30 ± 0.66 mmol/L, P < 0.001), low-density lipoprotein cholesterol (LDL) (7.9 ± 25.1 mg/dL or 0.2 ± 0.65
mmol/L, P < 0.001), hemoglobin A1c (HgbA1c) (0.20 ± 0.64%, P = 0.001), insulin (3.8 ± 11 microU/ml or 26.6 ± 76.4 rmol,
P < 0.001) and ultra sensitive C-reactive protein (US - CRP) (0.9 ± 4.8 mg/dL or 7.3 ± 40.2 nmol/L, P = 0.012), an increase in
mean high-density lipoprotein cholesterol (HDL) (3.7 ± 8.4 mg/dL or 0.1 ± 0.22, P < 0.001), and decreased use of
medications.
Conclusion: Implementation of a comprehensive lifestyle modification program among adults with common
chronic conditions results in significant and clinically meaningful improvements in biometric and laboratory
outcomes after 6 months.
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Interactions between lifestyle and genetic factors cause the
development and progression of a spectrum of chronic
conditions, including obesity, type 2 diabetes mellitus,
hypertension, cardiovascular disease and several types of
cancer. For some of these major causes of mortality, not
only in Western societies but globally, more than 80% of
attributable risks may be related to environmental, primar-
ily lifestyle factors [1,2]. In a recent prospective study, par-
ticipants who were successful in maintaining body mass
index below 30, not-smoking, exercising about 3.5 hrs per
week and eating mostly plant-based diets with limited
amount of meat had a 78% lower risk of developing
chronic disease than those without a healthy lifestyle fac-
tor [3]. It is, therefore, not surprising that health-promot-
ing lifestyle behaviors are prominently included in practice
guidelines for prevention or management of most chronic
conditions [4]. Several groups of investigators have suc-
cessfully used comprehensive lifestyle interventions for
treatment of chronic conditions, including coronary artery
disease, metabolic syndrome and type 2 diabetes mellitus
[5-9].
Without addressing the key underlying causes of mod-
ern chronic conditions, that is, lifestyle factors, it is hard
to imagine that optimal healthcare can be delivered for all
citizens at reduced cost and in a long-term, sustainable
fashion [10]. At the Cleveland Clinic, in late 2008 Lifestyle
180
® was launched with the goal of mitigating the physical
and fiscal consequences of preventable chronic diseases.
This program employs a system of class-based instruction
and ongoing follow-up for participants with common
chronic diseases around three key areas: nutrition, physical
activity, and stress management. Here, we report findings
for participants who completed six months of the
program.
Methods
Participants
Participants who had at least one of 8 chronic conditions
(obesity, hypertension, hyperlipidemia, diabetes, non-alco-
holic fatty liver disease, multiple sclerosis, early stage
breast or prostate cancer) and had been seen by the pri-
mary care physician within three months of enrollment
and had provided a note of medical clearance were eligible
for participation in the program. Patients who smoked,
first enrolled in the Cleveland Clinic’s tobacco cessation
program before being permitted to enroll in Lifestyle 180.
Patient recruitment was threefold: self-referral, physician-
referral or sponsorship by local self-insured employers.
Prior to starting Lifestyle180, participants completed an
intake packet that included past medical and surgical his-
tories, pertinent social history, medication use, psychoso-
cial questionnaires and a 1-day food diary.
Considering guidelines from the Third Report of the
National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III)
[11], the diagnosis of hyperlipidemia was used for partici-
pants with:Triglyceride ≥ 150 mg/dL; Total cholesterol ≥
200 mg/dL; LDL cholesterol ≥ 130 mg/dL; HDL choles-
terol < 40 mg/dL for males and < 50 mg/dL for females,
or normal lipids but participant was taking anti-hyperlipi-
demia medication. The diagnosis of hypertension was
used for participants with blood pressure ≥ 140/90 mmHg
at each of two or more visits taken on separate days or for
participants with a normal blood pressure but taking anti-
hypertensive medication. For obesity diagnosis, we used
the recommended classifications for BMI adopted by the
National Institute of Health and World Health Organiza-
tion [12]. Overweight – BMI ≥25.0 to 29.9 kg/m2; Obesity
– BMI ≥30 kg/m2;O b e s i t yC l a s sI– BMI of 30.0 to 34.9
kg/m2; Obesity Class II – BMI of 35.0 to 39.9 kg/m2 and
Obesity Class III – BMI ≥40 kg/m2. Diagnostic criteria for
pre-diabetes and diabetes were from the American Dia-
betes Association, Diagnosis and Classification of Diabetes
Mellitus from January 2011 [13]. Pre-diabetes was indi-
cated by fasting plasma glucose of 100 mg/dL to 125 mg/
dL or hemoglobin A1c 5.7-6.4%. For diabetes diagnosis we
used fasting plasma glucose of ≥126 mg/dL or hemoglobin
A1c ≥ 6.5%. The International Diabetes Federation criteria
were used for diagnosis of metabolic syndrome [14]. A
person to be defined as having the metabolic syndrome
must have central obesity (waist circumference ≥ 94 cm
for men and ≥ 80 cm for women) plus any two of the fol-
lowing four factors: raised triglyceride level ≥ 150 mg/dL,
reduced HDL cholesterol (< 40 mg/dL in males and < 50
mg/dL in females, raised blood pressure (systolic BP ≥ 130
mm Hg or diastolic ≥ 85 mm Hg or raised fasting plasma
glucose ≥ 100 mg/dL.
Lifestyle intervention was additive to the treatment plan
of all participants who continued medical care from their
pre-existing primary care physicians. Participants were
instructed to contact their primary physician to adjust
medications when deemed necessary, for example when
participants’ blood pressure and glucose readings started
to decrease into subnormal ranges. All hypertensive or
diabetic patients were encouraged to monitor daily their
blood pressure or fasting glucose, respectively.
An initial 48 hrs of lessons curriculum was taught twice
p e rw e e k ,i nf o u r - h o u rs e s s i o n se a c ho v e rt h ef i r s ts i x
weeks, called an Immersion Phase. During this period, the
first four-hour session of the week was divided into 60
minutes of participant physical activity and 90 minutes of
participant cooking and nutrition as well as stress manage-
ment classes, while during the second session of the week,
60 minutes period was devoted to participant exercise and
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metric one-on-one sessions each. The follow-up phase
included three components to help maintain behavioral
changes. These included 1) on-site classes at weeks 10, 18
and 30 that followed the same four-hour structure as
occurred during the Immersion phase on the second day
of the week, 2) a weekly e-mail newsletter and 3) the
buddy system. Buddies were assigned within each group
during the initial six-week session and were asked to keep
in daily contact.
Intervention
Lifestyle 180 was designed by taking into account find-
ings that behaviorally-based lifestyle modification
approaches increase the likelihood of sustained changes
[15].
Multiple modalities are incorporated into the curricu-
lum, including face-to-face interactions, individually-
tailored and group-tailored education sessions and coun-
seling to encourage internal motivation. Participants
receive a short syllabus written at 5th grade level. Three
key, closely interconnected, elements of the Lifestyle 180
curriculum included nutrition, physical activity and stress
management. Participants enrolled since October 2008
until April 2010 were included in this analysis.
The Nutrition Module
The primary goal for the nutrition curricular component
was to alter patients’ diets to foster measurable improve-
ments in biometric and laboratory disease markers. Nutri-
tional aspects of the program most closely align with the
Mediterranean diet [16]. The Lifestyle 180 program elimi-
nates trans fats as well as added sugars and syrups, limits
saturated fat to < 4 gm/meal (fish, skinless chicken and
skinless turkey breast being the only types of animal food
sources) and substitutes only 100% whole grains/grain
products for processed grain foods. Besides complex car-
bohydrates, Lifestyle 180 nutritional approach promotes
an increase in intake of plant foods to provide a spectrum
of phytochemicals exerting diverse beneficial biological
functions [17]. Improved glycemic control may help
reverse or stabilize consequences of diseases such as dia-
betes and hypertension and possibly beneficially affect
aging by activation of the human transcriptional machin-
ery homologue of Caenorhabditis elegans DAF-16 gene
complex [18-20]. This food strategy is also likely to pro-
mote weight loss, although this is not the primary goal of
Lifestyle 180 [21].
The nutritional component of Lifestyle 180 was team-
taught, with a chef and a registered dietitian. First, the
chef worked with participants in the teaching kitchen. In
an adjoining dining room/classroom, while participants
were eating a meal they helped prepare, the dietitian con-
ducted a seminar and guided a discussion about the
nutritional aspects of what they had cooked as well as a
covered topic of the day. To motivate participants to
change how and what they eat, they were engaged into
meal preparation in the kitchen. Gaining confidence with
the kitchen equipment and different types of foods as well
as learning how to manage time during meal preparation
were considered important elements of the efforts to
increase the likelihood that participants will change their
dietary habits. As part of the nutrition education of partici-
pants, one class during the Immersion Phase involved a
grocery store experience. In this environment, participants
learned how to read nutrition and ingredient labels, what
to avoid in packaged foods and how to “shop” ag r o c e r y
store (i.e. what aisles to avoid, which to frequent).
The Physical Activity Module
The goal of the physical activity component of Lifestyle
180 was to increase both endurance and strength of parti-
cipants. Current guidelines for adults recommend at least
150 minutes of physical activity per week to maintain fit-
ness levels and at least 200 minutes per week for waist cir-
cumference reduction and weight loss [22]. An exercise
instructor led the class in the Lifestyle 180 Fitness Center
that included progressive cardiovascular and endurance
training as well as resistance training. Patients chose
between treadmills, elliptical machines, stationary bicycles
or Concept Rowers. Resistance equipment includes dumb-
bells (2-15 lb each), stretch bands (resistance tubing: extra
light, light, medium and heavy) and medicine balls (2-15
lbs each). The goal was to teach participants how to
engage in physical activities in a safe and effective manner
and to enable them to gain the skills to exercise and pro-
gress on their own, including resistance exercise. They
were taught that increased resistance type activity helps
lose and maintain weight loss. In particular, visceral adi-
pose tissue is preferentially lost, while maintaining muscle
mass [23,24]. Patients were encouraged to wear ped-
ometers that were provided at start of the Program, with a
goal of 10,000 steps per day and to record their steps on a
daily diary sheet [25,26]. These data were used to monitor
participants’ progress in exercise.
The Stress Management Module
This component was team-taught, with a restorative yoga
therapist and a behavioral health specialist. To sustain
healthy lifestyle modifications, behavioral interventions
were implemented during the course of the program.
Those included goal setting, keeping records of lifestyle
practices, social support, cognitive restructuring and pro-
blem solving. Patients learned meditation and mindful-
ness practices and performed simple yoga poses initially
sitting or standing and at later stages of the program
lying down. Regular elicitation of the “relaxation
response”, the physiological opposite of the “fight or
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improve medical symptoms in patients with any of a
wide array of medical conditions [27]. These practices
were integrated into the program to teach participants
how to be present in the moment, more aware of their
thoughts and feelings to recognize old thoughts and pat-
terns that no longer serve them and release those unhelp-
ful ways of thinking and believing. The focus was on
accountability and compliance with the program and for
that purpose a daily diary checklist was reviewed in each
class by the behavioral health specialist and weekly by the
physician and nurse case manager during one-on-one
sessions with each participant.
Outcome Assessment
To measure the effectiveness of the Program, we estab-
lished an IRB-approved patient registry (Cleveland Clinic
Foundation IRB number 09-154) to collect biometric,
metabolic and psychosocial data. At each one-on-one ses-
sion, body weight, waist circumference, resting heart rate
and blood pressure were recorded while height was mea-
sured only at the start of the program for body mass index
(BMI, calculated as weight in kilograms divided by height
in meters squared) calculation. Participants were in socks
and lightly dressed when body weight and height were
measured. Waist circumference was measured by a tape
measure in the midspace between the lowest costal margin
and the iliac crest. Blood pressure was measured by the
standard manual protocol using sphygmomanometer. In
addition, patients were queried weekly regarding their
medications and changes in medications were recorded.
Patients and their physicians were given the results of the
biometrics and metabolic variables as they were obtained.
At the beginning of the program, participants completed a
1-day food diary that was analyzed by a registered dietitian
and reviewed with the participant during week one of the
Immersion phase.
Laboratory measures included total cholesterol (to con-
vert from mg/dL to millimoles per liter, divided by 38.67),
triglycerides (to convert from mg/dL to millimoles per
liter, divided by 88.57), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C) by
standard enzymatic methodology, hemoglobin A1c
(HgbA1c) (in percentages %) by turbidimetric inhibition
immunoassay, insulin (to convert from microIU/ml to
picomoles per liter divided by 6.94) by chemiluminescence
immunoassay, ultra sensitive C-reactive protein (US-CRP)
(to convert from mg/L to nanomoles per liter divide by
8.45) by immunoturbidometric assay and fasting plasma
glucose (to convert from mg/dL to millimoles per liter
divided by 18) by glucose hexokinase method. These
values were measured at the beginning of the study (week
1) and at weeks 6 and 30. Hemoglobin A1c was not evalu-
ated at week 6.
Statistical Methods
Continuous variables were presented as mean ± SD and
categorical variables as n (%). For univariable analyses,
changes in outcomes at 6 and 30 weeks from baseline
were assessed with the paired t-test. Analysis of covariance
was used to assess the relationship between weight loss
and baseline variables obesity status, diabetic status, hyper-
lipidemia, hypertension, metabolic syndrome while adjust-
ing for age, gender and payment options. We also report
the percentage of participants who experience weight loss
of 2.3 kg or more, that is, beyond the change expected
with normal daily weight fluctuation [28]. Results estimate
changes from baseline and not efficacy of the wellness pro-
gram. Patients with incomplete data at either baseline or
follow-up were excluded when assessing change or per-
cent change from baseline, as were patients with missing
covariables for multivariable models. No imputation of
data of missing data values was done. All reported P values
are two-sided and the significance level was 0.05 for each
hypothesis; a Bonferroni adjustment for multiple compari-
sons over time within each hypothesis was made (i.e., sig-
nificance criterion at each of 6 and 30 weeks was 0.05/2 =
0.025). SAS statistical software, Carey, NC, was used for all
analyses.
Results
Characteristics of participants
Baseline characteristics of participants are shown in
Table 1. The mean age of 429 participants was 52 years,
more participants were female (65%), 32% of participants
had diabetes, 59% had hyperlipidemia, 63% had hyperten-
sion, 80% were obese and 59% fulfilled the diagnostic cri-
teria for metabolic syndrome and 40% for pre-diabetes
[13,14]. The number of participants with other chronic
conditions, including breast and prostate cancer, fatty
liver and multiple sclerosis was much smaller (less
than 5%).
At week 6 (the end of the Immersion Phase) 404/429
(94%) of participants had biometric measurements taken
and 396/429 (92%) had labs drawn, while at week 30,
2 4 4 / 4 2 9( 5 7 % )r e t u r n e do nt i m ef o raf o l l o wu pa n d
299/429 (70%) had labs drawn.
There were few, but important differences in mean base-
line variables between these participants who had either
biometric or metabolic data available at their week 30 visit
and those who did not, six week variables, or change from
baseline to six weeks. Specifically, those who had week 30
biometrics completed were less likely to have obesity and
greater lowering of mean cholesterol and LDL at six weeks
than those who did not have week 30 data. Those who had
week 30 cholesterol data (as an indicator of blood work
being completed) were more likely to have greater lower-
ing in mean weight, triglycerides, cholesterol and LDL
than those with cholesterol levels not available (Table 2).
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Table 3 presents descriptive statistics between baseline, 6
and 30 weeks (Figure 1). Mean weight change over 30
weeks was 6.8 ± 6.9 kg (Table 4). Of 244 participants who
were measured at both baseline and 30 weeks, 183 (75%)
had 2.3 kg or more weight loss, 66 (27%) had over a 5%
weight loss and 67 additional (28%) had over a 10% weight
loss; 24 (10%) of participants gained weight. The mean
body mass index at 30 weeks was 33 ± 8 kg/m
2, and mean
waist circumference was 105 ± 16 cm. The mean ± SD
systolic blood pressure at 30 weeks was 129 ± 14 mmHg.
All biometric changes at 6 and 30 weeks were significantly
decreased from baseline (paired t-test, all P < 0.001, except
systolic blood pressure (P = 0.022)) (Table 4).
Metabolic changes
Results for metabolic measures are presented in Table 5
at each point in time, while changes from baseline are
shown in Table 6 and Figure 2. Means of all metabolic
measures were significantly lower at 6 weeks compared
with baseline (all P < 0.025). Mean glucose, total choles-
terol, triglycerides, LDL, HgbA1c, insulin and US-CRP
were also significantly lower at 30 weeks compared with
baseline, while mean HDL levels rose 3.7 ± 8.4 mg/dL
(0.10 ± 0.22 mmol/L) (P < 0.001). In general, changes at
30 weeks were sustained, but sometimes less than at 6
weeks.
Change in metabolic syndrome status
By International Diabetes Federation criteria [14], 247
(59%) out of 422 participants were identified as having
metabolic syndrome at baseline. Of the 382 participants
for whom metabolic syndrome status (yes or no) could
be determined at both baseline and 6 weeks, the percent
with metabolic syndrome dropped from 58% (223/382)
at baseline to 44% (167/382) at 6 weeks (McNemar’s
test, P < 0.001). Similarly, the percent with metabolic
syndrome dropped from 54% (138/257) at baseline to
37% (94/257) at 30 weeks (P < 0.001).
Relationship between clinical conditions and weight loss
Table 7 shows the relationship between clinical conditions
a n dw e i g h tl o s sa t6a n d3 0w e e k sf r o mb a s e l i n e .M e a n
weight loss was higher in the obese than in non-obese par-
ticipants at both 6 weeks (4.2 ± 2.7 vs. 2.3 ± 1.9 kg, multi-
variable P < 0.001) and 30 weeks (7.6 ± 7.4 vs. 4.2 ± 4.1
kg, multivariable P < 0.001). However, there was no differ-
ence in mean percent weight loss between the obese and
non-obese participants at either 6 weeks (multivariable
P = 0.033) or 30 weeks (multivariable P = 0.038). The fac-
tors diabetic, hyperlipidemia, hypertension, and metabolic
syndrome were not associated with the weight loss at 6
and 30 weeks (All P > 0.025).
Change in medication use
The summary of self-reported changes in medications for
diabetes, hyperlipidemia and hypertension at week 30 is
s h o w ni nT a b l e8 .P a r t i c i p a n t s ’ primary physicians
adjusted medications (not the Lifestyle 180 medical
team) as deemed necessary. Medication changes included
beneficial categories of a) stopped medication (151 medi-
cations), b) decreased dose of medication (89 medica-
tions) or c) avoided medication (24 medications).
Participants in the “avoided” category had, for example,
abnormally elevated LDL cholesterol or hemoglobin A1c
or were diagnosed with hypertension at baseline and
were advised by their primary care physicians to start
taking medications, but they refused. At week 30 their
blood tests, or blood pressure were within normal ranges
and they thus avoided the need to use a particular medi-
cation. On the opposite side, there were participants
whose baseline or week 6 laboratory findings and blood
pressure values were consistently abnormal or did not
improve thus requiring that they start taking new medi-
cations (a total of 62 medications, 36 of those for uncon-
trolled hypertension) or increase the dose of their current
Table 1 Basic Characteristics of Patients (N = 429)
a
Variable Statistics
b
Female N (%) 278 (65)
Obese (BMI > 30) N (%) 345 (80)
Pre-diabetes N (%) 170 (40)
Diabetes N (%) 139 (32)
Hyperlipidemia N (%) 255 (59)
Hypertension N (%) 270 (63)
Metabolic syndrome N (%)
c 247 (59)
Age (years) 52 ± 11
Height (cm) 168 ± 9
Weight (kg) 103 ± 25
BMI (kg/m
2)3 7 ± 8
Waist (cm)
d 114 ± 18
SBP (mmHg) 132 ± 15
DBP (mmHg) 82 ± 10
Heart rate (bpm) 78 ± 11
Fasting Glucose (mg/dL)
e 108 ± 35 (6.0 ± 1.9 mmol/L)
Triglycerides (mg/dL)
f 137 ± 81(1.5 ± 0.9 mmol/L)
Cholesterol (mg/dL)
f 187 ± 39 (4.8 ± 1.0 mmol/L)
HDL (mg/dL)
f 51 ± 15 (1.3 ± 0.4 mmol/L)
LDL (mg/dL)
e 109 ± 33 (2.8 ± 0.9 mmol/L)
HgbA1c (%)
j 6±1
Insulin (microU/mL) 19 ± 18 (131 ± 122 rmol)
US-CRP (mg/dL) 5 ± 8 (45 ± 66 nmol/L)
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HDL, high-density lipoprotein cholesterol; LDL, low-
density lipoprotein cholesterol; HgbA1c, hemoglobin A1c; US-CRP, ultra
sensitive c-reactive protein.
a Insulin (N = 271) and US-CRP (N = 285) only measured beginning June 2009.
b N (%) or mean ± SD.
c, d, e, f, j indicate 7, 1, 9, 6 and 34 missing data points, respectively.
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a
Variable 30-week Weight available P
value
30-week Cholesterol available P value
Yes (N = 243) No N = (186) Yes
(N = 295)
No
(N = 128)
Baseline conditions:
Diabetes N (%) 176 (72) 133 (72) 0.97 220 (75) 88 (69) 0.26
Obesity (BMI> 30) N (%)
N (%)
185 (76) 160 (95) 0.011
b 232 (79) 108 (84) 0.17
Hyperlipidemia N (%) 151 (62) 104 (56) 0.19 185 (63) 68 (53) 0.065
Hypertension N (%) 155 (64) 115 (62) 0.68 193 (65) 73 (57) 0.10
Metabolic syndrome N (%) 135 (56) 112 (61) 0.33 175 (60) 71 (56) 0.47
Biometrics at week 6:
Weight (kg) 95 ± 22 105 ± 26 < 0.001
b 96 ± 22 105 ± 26 0.002
b
Waist (cm) 107 ± 15 112 ± 17 0.002
b 108 ± 15 112 ± 18 0.046
b
Body mass index (kg/m
2) 34 ± 7 37 ± 8 < 0.001
b 34 ± 7 37 ± 8 0.004
b
Systolic blood pressure (mmHg) 126 ± 13 127 ± 15 0.66 126 ± 13 127 ± 15 0.69
Diastolic blood pressure (mmHg) 79 ± 8 79 ± 9 0.78 79 ± 8 79 ± 9 0.90
Heart rate (bpm) 71 ± 11 73 ± 12 0.056 71 ± 11 74 ± 12 0.014
b
Metabolic variables at week 6:
Glucose (mg/dL) 101 ± 25 104 ± 27 0.32 101 ± 24 104 ± 30 0.40
(mmol/L) 5.6 ± 1.4 5.8 ± 1.5 5.6 ± 1.3 5.8 ± 1.7
Triglycerides (mg/dL) 102 ± 49 115 ± 54 0.02
b 103 ± 49 118 ± 57 0.023
b
(mmol/L) 1.2 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 1.3 ± 0.6
Cholesterol (mg/dL) 164 ± 35 170 ± 38 0.11 164 ± 36 171 ± 37 0.08
(mmol/L) 4.2 ± 0.9 4.4 ± 1.0 4.2 ± 0.9 4.4 ± 1.0
High-density lipoprotein (mg/dL) 51 ± 15 48 ± 13 0.08 50 ± 14 49 ± 15 0.33
Cholesterol (mmol/L) 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.4 1.3 ± 0.4
Low-density lipoprotein (mg/dL) 92 ± 29 99 ± 34 0.06 93 ± 30 99 ± 33 0.11
Cholesterol (mmol/L) 2.4 ± 0.7 2.6 ± 0.9 2.4 ± 0.8 2.6 ± 0.9
Change in biometrics from baseline to six weeks:
Weight (kg) -4.0 ± 2.5 -3.6 ± 2.8 0.16 -4.1 ± 2.6 -3.1 ± 2.7 < 0.001
b
Waist (cm) -4.0 ± 4.1 -4.4 ± 4.2 0.36 -4.2 ± 4.1 -4.0 ± 4.4 0.66
Body mass index (kg/m
2) -1.4 ± 0.9 -1.3 ± 1.0 0.12 -1.5 ± 0.9 -1.1 ± 0.9 < 0.001
b
Systolic blood pressure (mmHg) -5.1 ± 15.7 -5.1 ± 15.2 0.98 -5.8 ± 15.1 -3.7 ± 16.6 0.24
Diastolic blood pressure (mmHg) -2.7 ± 8.6 -3.9 ± 10.9 0.24 -3.1 ± 9.2 -3.5 ± 10.7 0.75
Heart rate (bpm) -4.7 ± 1.7 -6.2 ± 11.2 0.20 -5.4 ± 10.9 -5.3 ± 12.8 0.92
Change in metabolic variables from baseline to six weeks:
Glucose (mg/dL) -6 ± 24 -6 ± 25 0.96 -6 ± 22 -7 ± 29 0.67
(mmol/L) -0.3 ± 1.3 -0.3 ± 1.4 -0.3 ± 1.2 -0.4 ± 1.6
Triglycerides (mg/dL) -31 ± 55 -23 ± 51 0.12 -32 ± 55 -17 ± 49 0.010
b
(mmol/L) -0.4 ± 0.6 -0.3 ± 0.6 -0.4 ± 0.6 -0.2 ± 0.6
Cholesterol (mg/dL) -25 ± 26 -17 ± 25 < 0.001
b -24 ± 28 -14 ± 19 < 0.001
b
(mmol/L) -0.7 ± 0.7 -0.4 ± 0.6 -0.6 ± 0.7 -0.4 ± 0.5
High-density lipoprotein (mg/dL) -2.3 ± 7 -1.7 ± 6 0.37 -1.9 ± 7.0 -2.4 ± 6.0 0.50
Cholesterol (mmol/L) -0.1 ± 0.2 -0.0 ± 0.2 -0.0 ± 0.2 -0.1 ± 0.2
Low-density lipoprotein (mg/dL) -17 ± 21 -10 ± 21 < 0.001
b -17 ± 22 -8 ± 19 < 0.001
b
Cholesterol (mmol/L) -0.5 ± 0.6 -0.3 ± 0.5 -0.4 ± 0.6 -0.2 ± 0.5
a Statistics represent N (%) and mean ± SD. P values from the chi-square test or t-test, as appropriate.
b Significant if P < 0.05 (no correction testing at multiple weeks, to be conservative).
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changes were made in the same category (for example, a
diuretic was replaced with a calcium channel blocker)
( d a t an o ts h o w n ) .A ss h o w ni nT a b l e8 ,f o re v e r yn e w l y
started medication or one with increased dose, 3.3 medi-
cations were stopped, reduced in dose or avoided. This
ratio was even better (4.0) in case of diabetes and hyperli-
pidemia medications.
Discussion
Preventable chronic diseases continue to drive health
care costs substantially and importantly upward, in part
due to a lack of sustainable treatment options. Specific
medications, such as cholesterol-lowering and diabetes
medications target mostly one chronic disease-associated
abnormality of elevated LDL cholesterol or plasma
glucose, respectively, rather than the cause of the
abnormality. While surgical interventions successfully
treat obesity and a spectrum of associated metabolic
changes, they poorly address the behavioral and lifestyle-
related factors that led to the development of chronic
conditions in the first place. In contrast, comprehensive
lifestyle interventions may result in multiple physiological
systems changes including behavior modifications that
support long-term healthier lifestyle choices [5,29].
Here, we report findings that a tri-pronged lifestyle
intervention consisting of diet, physical activity and stress
management improves disease-associated markers of par-
ticipants with multiple chronic conditions. All measured
biometric and laboratory variables significantly improved
after just 6 weeks of intervention. Beneficial changes in
blood pressure and glucose were observed in many partici-
pants by the second week of the program, thus supporting
previously reported observations of the quick onset of
measurable benefits that follow a comprehensive lifestyle
intervention [8]. Serum HDL cholesterol decrease after 6
weeks was most likely associated with early weight loss, as
reported [30]. Nevertheless, reductions in total cholesterol
are more profound than in HDL cholesterol, resulting in
improved ratio of total cholesterol to HDL cholesterol, an
Table 3 Biometric outcomes: descriptive statistics by week of follow-up
Factor Week One
(N = 429)
Week Six
(N = 404)
Week 30
(N = 244)
Mean ± SD Min-Max Mean ± SD Min-Max Mean ± SD Min-Max
Weight (kg) 103 ± 25 49 - 205 99 ± 24 46 - 200 92 ± 22
a 46 - 216
Waist (cm) 114 ± 18
a 66 - 167 109 ± 16
b 66 - 163 105 ± 16
c 66 - 186
SBP (mmHg) 132 ± 15 92 - 188 127 ± 14 94 - 181 129 ± 14
b 100 - 180
DBP(mmHg) 82 ± 10 50 - 120 79 ± 8 48 - 112 79 ± 8
b 58 - 98
HR (bpm) 78 ± 11 52 - 114 72 ± 12
a 43 - 115 71 ± 10 40 - 108
BMI (kg/m
2) 37 ± 8 19 - 70 35 ± 8 19 - 69 33 ± 8
a 18 - 74
Abbreviations: BMI, body mass index.
a, b, c indicate 1, 2, and 6 missing data points, respectively.
Figure 1 Boxplots comparing weeks 1, 6 and 30 in each
biometric variable using all non-missing data. SBP denotes
systolic blood pressure (mmHg). Box shows the interquartile range;
horizontal line marks the median; whiskers extend to high and low
values within 1.5 interquartile range of the box; circles are values
beyond 1.5 interquartile ranges of the box; diamond shows the
mean.
Table 4 Biometric outcomes: changes from baseline to
six and thirty weeks
Factor Week 6 change from
baseline
(N = 404)
Week 30 change from
baseline
(N = 244)
Mean ± SD P value
a Mean ± SD P value
a
Weight (kg) -3.8 ± 2.6 < 0.001 -6.8 ± 6.9
c < 0.001
Waist (cm) -4.2 ± 4.2
b < 0.001 -6.1 ± 7.3
d < 0.001
SBP (mmHg) -5.1 ± 15.5 < 0.001 -2.5 ± 17.1
e 0.022
DBP(mmHg) -3.2 ± 9.6 < 0.001 -2.5 ± 10.0
e < 0.001
HR (bpm) -5.3 ± 11.5
c < 0.001 -5.3 ± 11.5 < 0.001
BMI (kg/m
2) -1.3 ± 0.9 < 0.001 -2.4 ± 2.4
c < 0.001
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR, heart rate.
a P value from paired t-test, significant if P < 0.025.
b, c, d, e indicate 3, 1, 6 and 2 missing data points, respectively.
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Although HDL cholesterol generally decreases during
weight loss, it increases following weight maintenance in
proportion to the amount of weight that is lost [32,33]. At
week 30, HDL cholesterol is significantly higher than at
the baseline and the total cholesterol/HDL ratio improves
further. Fasting triglyceride level is also significantly
reduced at both points in time (week 6 and 30) compared
with baseline, reflecting the observations that triglycerides
improve after weight loss [34]. Fasting hypertriglyceride-
mia is an established risk factor for cardiovascular disease
and may predict disease progression [35]. In addition, TG/
HDL ratio, a possible powerful predictor of extensive cor-
onary artery disease is also improved, that is, decreased
significantly [36]. In our study, we did not examine if these
beneficial changes lead to better cardiovascular outcomes.
In a comprehensive lifestyle intervention similar to ours,
where a low-fat plant-based diet rather then a Mediterra-
nean-style diet was used, reductions in total and LDL cho-
lesterol were of greater magnitude than in this study and
were associated with the arrest and/or reversal of coronary
artery disease [5,37].
A large proportion of the global burden of chronic
diseases, particularly cardiovascular disease, obesity and
some cancers, involves non-resolving, chronic inflamma-
tion [38]. Lifestyle 180 interv e n t i o nr e s u l t e di ns i g n i f i -
cantly healthier markers of glucose metabolism and
inflammation (Table 6). Although measurements of
insulin and US-CRP were initiated at later stages of the
program and data were available for smaller number of
participants, these results show large percentage
decreases, strengthening the evidence that these lifestyle
interventions may be used as anti-inflammatory thera-
pies to treat insulin resistance, beneficially impact meta-
bolic syndrome and associated chronic diseases [39]. It
is, therefore, not surprising that the percent of partici-
pants with metabolic syndrome was significantly lower
after 6 months of lifestyle interventions (an estimated
relative 32 percent lower, from 54% to 37%).
Here we report only the outcomes for those partici-
pants who had biometric and lab measurements. These
participants had greater lowering of mean weight and
cholesterol at week 6 than those who did not attend
this follow up. Thus, it is likely that those who wit-
nessed greater early successes in their outcomes were
more motivated to remain engaged in the program. We
were unable to obtain biometric and laboratory mea-
surements of patients who dropped out at 6 months,
but the observed differences at 6 weeks suggest that
those patients who dropped out at 6 months may have
done so because their outcomes were not as good as
for those who remained. At six months, 30-43% attri-
tion rate (laboratory data and biometrics, respectively)
was comparable to some lifestyle intervention pro-
grams, but lower than in others [40-42]. More than
75% of participants who enrolled into the program
Table 5 Metabolic outcomes by week
a
Factor Units Week One
(N = 423)
Week Six
(N = 396)
Week 30
(N = 299)
Mean ± SD Min - Max Mean ± SD Min - Max Mean ± SD Min -Max
Glucose (mg/dL) 108 ± 35
b 67 - 330 102 ± 27
c 62 - 264 103 ± 29 59 - 339
(mmol/L) 6.0 ± 1.9 3.7 - 18.3 5.7 ± 1.5 3.4 - 14.7 5.7 ± 1.6 3.3 - 18.8
Triglycerides (mg/dL) 137 ± 81 34 - 839 107 ± 51 34 - 405 109 ± 52
d 32 - 331
(mmol/L) 1.5 ± 0.9 0.4 - 9.5 1.2 ± 0.6 0.4 - 4.6 1.2 ± 0.6 0.4 - 3.7
Cholesterol (mg/dL) 187 ± 39 82 - 307 166 ± 36 80 - 294 179 ± 38
d 93 - 290
(mmol/L) 4.8 ± 1.0 2.1 - 7.9 4.3 ± 0.9 2.1 - 7.6 4.6 ± 1.0 2.4 - 7.5
HDL (mg/dL) 51 ± 15 24 - 128 50 ± 14 21 - 110 55 ± 16
d 21 - 147
(mmol/L) 1.3 ± 0.4 0.6 - 3.3 1.3 ± 0.4 0.5 - 2.8 1.4 ± 0.4 0.5 - 3.8
LDL (mg/dL) 109 ± 33
b 21 - 218 95 ± 31 17 - 225 102 ± 32
e 26 - 215
(mmol/L) 2.8 ± 0.9 0.5 - 5.6 2.5 ± 0.8 0.4 - 5.8 2.6 ± 0.8 0.7 - 5.6
HgbA1c (%) 6 ± 1
c 5 - 13 N/A N/A 6 ± 1
f 5-1 0
Insulin (microU/dL) 19 ± 18 3 - 134 14 ± 14 1 - 126 13 ± 10 0.5 - 72
(pmol/L) 131 ± 122 17 - 930 97 ± 97 7 - 877 87 ± 73 3.5 - 500
US-CRP (mg/mL) 5 ± 8 0.1 - 88 4 ± 5 0.2 - 33 4 ± 6 0.2 - 39
(nmol/L) 45 ± 66 0.8 - 740 33 ± 45 1.7 - 278 33 ± 48 1.7 - 331
Abbreviations: HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; HgbA1c, hemoglobin A1c; US-CRP, ultra sensitive c-reactive
protein. N/A, no required measurement at six weeks.
a N = 271, 266 and 185 for insulin and N = 285, 273 and 201 for US-CRP at weeks 1, 6, and 30, respectively, since neither parameter measured before June 2009;
b, c, d, e, f indicate 3, 28, 7, 2, 1 and 15 missing data points, respectively.
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had at least one of the chronic conditions and fre-
quently included those who made little health improve-
ments after participating in standard disease
management programs. No pre-enrollment evaluation
was conducted to ascertain whether potential partici-
pants were considering making lifestyle changes and
whether they could count on support of their spouses
and families. Local self-insured employers paid in full
the costs of the program for their participants (with
exception of 26 participants who paid 20% of the
costs). Participants were not penalized if they missed
the classes and no financial incentives (besides paying
for the program itself) were provided to them to attend
the classes. It is possible that the attendance at week
30 follow up would have been better if some of these
factors were considered and follow up visits were more
frequent, as evidenced by changes to the program (for
example, shorter Immersion phase of 4 weeks instead
of original 6 weeks has decreased spacing between the
visits, the longest being now 2 months instead of 3
months) we made (our subsequent data not reported
here). Adherence to lifestyle interventions seems to
increase with multiple follow-up visits [43].
This study has several weaknesses. Pre-post type of
study is not suitable to establish causality and assess
how much of the observed changes are specifically due
to the program. A randomized clinical trial would be
needed for that purpose. However, implementation of a
comprehensive lifestyle intervention in a randomized
fashion is hampered by preferences of participants
(those who prefer to engage in lifestyle improvement
activities and those who don’t) and may suffer from
crossover problems [37]. Some of the observed changes
could have been due to the placebo effect and possibly
some other unidentified factors, not just to the partici-
pation in the lifestyle program per se.
Table 6 Metabolic outcomes: changes from baseline to six and thirty weeks
a
F Factor Units Change at week six
(N = 392)
Change at week thirty
(N = 295)
Mean ± SD P value
b Mean ± SD P value
b
Glucose (mg/dL) -6.3 ± 24.3
c < 0.001 -4.5 ± 29.6
e 0.009
(mmol/L) -0.35 ± 1.35 -0.25 ± 1.64
Triglycerides (mg/dL) -27.7 ± 53.8 < 0.001 -26.4 ± 58.5 < 0.001
(mmol/L) -0.31 ± 0.61 -0.30 ± 0.66
Cholesterol (mg/dL) -21.7 ± 25.9 < 0.001 -9.0 ± 29.5 < 0.001
(mmol/L) -0.56 ± 0.67 -0.23 ± 0.76
HDL (mg/dL) -2.0 ± 6.8 < 0.001 3.7 ± 8.4 < 0.001
(mmol/L) -0.05 ± 0.17 0.10 ± 0.22
LDL (mg/dL) -14.3 ± 21.6
d < 0.001 -7.9 ± 25.1 < 0.001
(mmol/L) -0.37 ± 0.56 -0.20 ± 0.65
HgbA1c (%) N/A N/A -0.2 ± 0.6
f < 0.001
Insulin (microU/dL) -4.4 ± 9.7 < 0.001 -3.8 ± 11.0 < 0.001
(pmol/L) -30.7 ± 67.4 -26.6 ± 76.4
US-CRP (mg/mL) -1.4 ± 6.4 < 0.001 -0.9 ± 4.8 0.012
(nmol/L) -11.9 ± 54.0 -7.3 ± 40.2
Abbreviations: HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; HgbA1c, hemoglobin A1c; US-CRP, ultra sensitive c-reactive
protein. N/A, no required measurement at six weeks.
a N = 250, 173 for insulin and N = 270, 198 for US-CRP since neither measured before June 2009.
b P value from the paired t-test, significant if P < 0.025.
c, d, e, f indicate 9, 1, 3, and 24 missing data points, respectively.
Figure 2 Mean change (97.5% CI) in metabolic outcomes at six
and thirty weeks from baseline. Abbreviations: HDL, high-density
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.
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for participation in the program. This self-selected
group of people who could financially afford the pro-
gram and were able to accommodate their schedules
during the first six weeks of the Immersion Phase are
clearly not representative of the general population. For
example, personality traits differ between obese persons
who enroll and those who do not enroll in comprehen-
sive lifestyle intervention programs [44]. Also, there was
a bias in selection of participants by their employers to
enroll in Lifestyle 180 as discussed above.
Because of only 6 months of intervention, inferences
about long-term effectiveness cannot be made. Longer
term data are needed to demonstrate that beneficial life-
style changes are sustainable for such a large percentage
of participants. An additional weakness of this study is
that we did not evaluate adherence to the program and
therefore we were unable to correlate the degree of
adherence to the lifestyle program with changes in risk
factors and to identify aspect(s) of lifestyle changes that
are the most important for good outcomes. The out-
comes data are reported for a heterogeneous group of
participants and a subgroup analysis would be needed
for better evaluation of chronic disease-specific out-
comes. In addition, one might argue that significant
improvements in lipids, glucose and inflammation mar-
kers could be the result of increased use of medications
rather than participation in lifestyle intervention. While
the cost-effectiveness analysis of the Lifestyle 180 pro-
gram (including changes in pharmaceuticals) is in pro-
gress (manuscript in preparation), as shown in Table 8,
for every newly started medication or one with increased
dose, 3.3 medications were stopped, reduced in dose or
avoided. This suggests that a spectrum of significant and
beneficial biometric and biomarker improvements
Table 7 Relationship between baseline conditions and weight change (kg) at 6 and 30 weeks
Factor Levels N Mean ± SD Difference in
means (95% CI)
c
P value
c
At 6 weeks
a:
Diabetes Yes 292 -3.9 ± 2.7 -0.11 (-0.72, 0.50) 0.73
No 112 -3.7 ± 2.5
Hyperlipidemia Yes 243 -3.8 ± 2.6 -0.01 (-0.51, 0.54) 0.96
No 161 -3.8 ± 2.8
Hypertension Yes 254 -3.9 ± 2.7 0.04 (-0.49, 0.57) 0.88
No 150 -3.7 ± 2.6
Metabolic syndrome Yes 234 -4.3 ± 2.7 -0.57 (-1.13, -0.01) 0.048
No 164 -3.2 ± 2.3
Obesity (BMI > 30) Yes 324 -4.2 ± 2.7 -1.61 (-2.26, -0.95) < 0.001
No 80 -2.3 ± 1.9 -0.64 (-1.24, -0.05)
d 0.033
At 30 weeks
b:
Diabetes Yes 176 -6.4 ± 6.6 1.22 (-0.91, 3.35) 0.26
No 67 -7.7 ± 7.7
Hyperlipidemia Yes 151 -6.1 ± 6.7 1.51 (-0.36, 3.39) 0.11
No 92 -7.9 ± 7.0
Hypertension Yes 155 -6.7 ± 7.1 0.32 (-1.60, 2.22) 0.74
No 88 -6.9 ± 6.6
Metabolic syndrome Yes 135 -7.3 ± 8.1 -0.69 (-2.63, 1.25) 0.48
No 104 -6.0 ± 4.9
Obesity (BMI > 30) Yes 185 -7.6 ± 7.4 -3.69 (-5.86, -1.52) < 0.001
No 58 -4.2 ± 4.1 -2.1 (-4.08, -0.12)
d 0.038
a Multivariable model (N = 398) including all five conditions in table plus age, gender, payment options.
b Multivariable model (N = 239) including all five conditions in table plus age, gender, payment options.
c Multivariable model results; significant if P < 0.025; difference in mean change for “Yes” minus “No”.
d Difference in mean percent change from baseline.
Table 8 Medication changes at 30 weeks
Diabetes Hyperlipidemia Hypertension Total
Stopped 33 39 79 151
Decreased 47 12 30 89
Avoided 3 18 3 24
Total 83 69 112 264
Started 12 14 36 62
Increased 9 3 6 18
Total 21 17 42 80
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medications.
Conclusions
Participation in a comprehensive Lifestyle 180 program
results in significant and rapid, as well as clinically and
biologically relevant improvements in biometric and
laboratory outcomes, including reduced need for medica-
tions, for adults with multiple chronic conditions. Further
follow up is needed to see if these beneficial changes are
sustained.
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